sellWeak cluster of 2
John Nuss sold $98k of VTYX
CHIEF SCIENTIFIC OFFICER at Ventyx Biosciences, Inc.. 12,675 shares at an average of $7.72, traded Dec 18, 2025, filed Dec 19, 2025.
Warning score
18Value
$98k
12,675 shares
Holdings after
489,481
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +10Trade size$98k at market
- 0Share of holdings soldSold 2.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-326892, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2025 | MOption exercise Common Stock | +34,930 | $0.00 | $0 | 502,156 | Dec 19, 2025 |
| Dec 18, 2025 | SOpen-market sale Common Stock | -12,675 | $7.72 | $98k | 489,481 | Dec 19, 2025 |
| Dec 17, 2025 | MOption exercise Restricted Stock Unitsderivative | -34,930 | $0.00 | $0 | 0 | Dec 19, 2025 |
Related signals
Other insiders at Ventyx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $365k 47,345 shares | -2% | |
| 15Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $2,019 1,887 shares | -0% | |
| 22Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $50k 21,119 shares | -4% | |
| 37Weak | VTYXbuy Ventyx Biosciences, Inc. | Sheila Gujrathi director | $301k 130,000 shares | - | |
| 5Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $30k 13,161 shares | -3% | |
| 55Moderate | VTYXbuy Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $960k 500,000 shares | +30% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.